Hepatocellular ballooning in nonalcoholic steatohepatitis: The pathologist's perspective

Expert Review of Gastroenterology and Hepatology

Volumn 5, Issue 2, 2011, Pages 223-231

  Lackner, Carolin ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

fat staining; hepatocellular ballooning; intermediate filament cytoskeleton; keratin 18; keratin 8; liver biopsy; NAFLD; NASH; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; oil red O

Indexed keywords

CELL DEGENERATION; CELL STRUCTURE; CHRONIC DISEASE; CYTOPLASM; CYTOSKELETON; DISEASE CLASSIFICATION; DISEASE SEVERITY; ENDOPLASMIC RETICULUM; HEPATOCELLULAR BALLOONING; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; LIVER BIOPSY; LIVER DISEASE; LIVER FIBROSIS; MALLORY DENK BODIES; MORPHOLOGY; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOGENESIS; PREVALENCE; PROTEIN MODIFICATION; REVIEW;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CHRONIC DISEASE; CYTOPLASM; CYTOSKELETON; DISEASE PROGRESSION; FATTY LIVER; FEMALE; HUMANS; KERATIN-18; KERATIN-8; LIVER; LIVER NEOPLASMS; MALE; MICE; PREVALENCE; PROGNOSIS;

EID: 79954455572     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.11.8     Document Type: Review

References (80)

1. Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu. Rev. Pathol. Mech. Dis. 5, 145-171 (2010).
2. Ludwig J, McGill DB, Lindor K. Review: non-alcoholic steatohepatitis. J. Gastroenterol. Hepatol. 12, 398-403 (1997).
3. Abdelmalek MF, Diehl AM. Nonalcoholic fatty liver disease as a complication of insulin resistance. Med. Clin. North Am. 91(6), 1125-1149, ix (2007). (Pubitemid 47625434)
4. Brunt E. Non-alcoholic fatty liver disease. In: MacSween's Pathology of the Liver (7th Edition). Burt AD, Portmann BC, Ferrel LD (Eds). Churchill Livingstone Elsevier, PA, USA, 367-397 (2007).
5. Lazo ML, Clark JM. The epidemiology of non-alcoholic fatty liver disease: a global perspective. Semin. Liver Dis. 28(4), 339-350 (2008).
6. Clark JM. The epidemiology of non-alcoholic fatty liver disease in adults. J. Clin. Gastroenterol. 40(Suppl. 1), S5-S10 (2006). (Pubitemid 44309537)
7. Falck-Ytter Y, Younossi ZM, Marchesini G et al. Clinical features and natural history of non-alcoholic steatosis syndromes. Semin. Liver Dis. 21(1), 17-26 (2001). (Pubitemid 32240483)
8. Bedgoni G, Miglioli L, Masutti F et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study Hepatology 42, 44-52 (2005). (Pubitemid 40911310)
9. Lonardo A, Bellini M, Tartoni P et al. The bright liver syndrome. Prevalence and determinants of a 'bright' liver echopattern. Ital. J. Gastroenterol. Hepatol. 29, 351-356 (1997). (Pubitemid 28059513)
10. Bellentani S, Saccoccio G, Masutti F et al. Prevalence and risk factors for hepatic steatosis in Northern Italy. Ann. Intern. Med. 132, 112-117 (2000). (Pubitemid 30044177)
11. Hilden M, Christoffersen P, Juhl E et al. Liver histology in a 'normal' population-examinations of 503 consecutive fatal traffc casualities. Scand. J. Gastroenterol. 12, 593-597 (1977). (Pubitemid 8149779)
12. Minervini MI, Ruppert K, Fontes P et al. Liver biopsy fndings from healthy potential living donors: reasons for disqualifcation, silent diseases and correlation with liver injury tests. J. Hepatol. 50, 501-510 (2009).
13. Nadalin S, Malago M, Valentin-Gamazo C et al. Preoperative donor liver biopsy for adult living donor liver transplantation: risks and benefts. Liver Transpl. 11, 980-986 (2005). (Pubitemid 41122457)
14. Ryan CK, Johnson LA, Germin BI et al. One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. Liver Transpl. 8, 1114-1122 (2002). (Pubitemid 35469871)
15. Tran TT, Changsri C, Shackleton CR et al. Living donor liver transplantation: histological abnormalities found on liver biopsies of apparently healthy potential donors. J. Gastroeneterol. Hepatol. 21, 381-383 (2006).
16. Tannapfel A, Denk H, Dienes HP et al. Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Grade 2 consensus-based guidelines. Pathologe 31, 225-237 (2010).
17. Sanyal AJ. AGA technical review on non-alcoholic fatty liver disease. Gastroenterology 123, 1705-1725 (2002). (Pubitemid 35231670)
18. Farrell GC, Chitturi S, Lau GK et al. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacifc region: executive summary. J. Gastroenterol. Hepatol. 22, 775-777 (2007). (Pubitemid 46911045)
19. Loria P, Adinolf LE, Bellentani S et al. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A Decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig Liver Dis. 42, 272-282 (2010).
20. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43, S99-S112 (2006).
21. Ratziu V, Bellentani S, Cortez-Pinto H et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J. Hepatol. 53, 372-384 (2010).
22. Naveau S, Giraud V, Borotto E et al. Excess weight is a risk factor for alcoholic liver disease. Hepatology 25, 108-111 (1997). (Pubitemid 27014994)
23. Powell EE, Jonson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology 42, 5-13 (2005). (Pubitemid 40911303)
24. Sumida Y, Eguchi Y, Ono M. Current status and agenda in the diagnosis of non-alcoholic steatohepatitis in Japan. World J. Hepatol 2, 374-383 (2010).
25. Brunt EM. Nonalcoholic steatohepatitis: pathologic features and differential diagnosis. Semin. Diagn. Pathol. 22, 330-338 (2005). (Pubitemid 44118640)
26. Straub BK, Schirrmacher P. Pathology and biopsy assessment of non-alcoholic fatty liver disease. Dig. Dis. 28, 197-202 (2010).
27. Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis 24, 3-20 (2004). (Pubitemid 38496045)
28. Neuschwander-Teri BA. Evolving pathophysiologic concepts in non-alcoholic steatohepatitis. Curr. Gastroenterol. Rep. 4, 31-36 (2002).
29. Skelly MM, James PD, Ryder SD et al. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J. Hepatol. 35, 195-199 (2001). (Pubitemid 32803474)
30. Ratziu V, Charlotte F, Heurtier A et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128, 1898-1906 (2005). (Pubitemid 40824701)
31. Vuppalanchi R, Ünalp A, Van Natta ML et al. Increased diagnostic yield from liver biopsy in suspected non-alcoholic fatty liver diseases (NAFLD) using multiple cores and multiple readings. Clin. Gastroenterol. Hepatol. 7(4), 481-486 (2009).
32. Schwimmer JB, Behling C, Newbury R et al. Histopathology of paediatric nonalcoholic fatty liver disease. Hepatology 42, 641-649 (2005). (Pubitemid 41233657)
33. Puri P, Baillie RA, Wiest MM et al. A lipidomic analysis of non-alcoholic fatty liver disease. Hepatology 46, 1081-1090 (2007). (Pubitemid 350144772)
34. Brunt EM, Janney CG, Bisceglie AM et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 94, 2467-2474 (1999). (Pubitemid 29420675)
35. Kleiner D, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313-1321 (2005). (Pubitemid 40770284)
36. Brunt EM. Histopathology of non-alcoholic fatty liver disease. Clin. Liver Dis. 13, 533-544 (2009).
37. Neuschwander-Teri BA, Caldwell S. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37, 1202-1219 (2003). (Pubitemid 36538699)
38. Ong J, Younossi ZM, Reddy V et al. Cryptogenic cirrhosis in posttransplantation nonalcoholic fatty liver disease. Liver Transplant. 7, 797-801 (2001). (Pubitemid 32851301)
39. Marrero JA, Fontana RJ, Su GL et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 36, 1349-1354 (2002). (Pubitemid 35403524)
40. Diniakos DG. Nonalcoholic fatty liver disease/non-alcoholic steatoheptitis: histological diagnostic criteria and scoring systems. Eur. J. Gastroenterol. Hepatol 22, 643-650 (2010).
41. Matsuda Y, Takada A, Kanayama R. et al. Changes in hepatic microtubules and secretory proteins in human alcoholic liver disease. Pharmacol. Biochem. Behav. 18 (Suppl. 1), 479-482 (1983).
42. Schaff Z, Lapis K. Fine structure of hepatocytes during the etiology of several common pathologies. J. Electron Microsc Tech. 14, 179-207 (1990). (Pubitemid 20090752)
43. Gores GJ, Herman B, Lemasters JJ. Plasma membrane bleb formation and rupture: a common feature of hepatocellular injury Hepatology 11, 690-698 (1990). (Pubitemid 20151750)
44. Caldwell S, Redick JA, Davis CA et al. Ultrastructural evaluation of hepatocytes with type 2 Mallory-Denk bodies: clues to ballooning in non-alcoholic steatohepatitis (NASH). Hepatology 46, 741A (2007).
45. Caldwell S, Ikura Y, Dias D et al. Hepatocellular ballooning in NASH. J. Hepatol. 53, 719-723 (2010).
46. Lackner C, Gogg-Kamerer M, Zatloukal K et al. Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis. J. Hepatol. 48, 821-828 (2008).
47. Zatloukal K, Stumptner C, Fuchsbichler A et al. The keratin cytoskeleton in liver diseases. J. Pathol. 204, 367-376 (2004). (Pubitemid 39468148)
48. Zatloukal K, French SW, Stumptner C et al. From Mallory to Mallory-Denk bodies: what how and why? Exp. Cell Res. 313, 2033-2049 (2007). (Pubitemid 46842981)
49. Lieber CS. Alcoholic liver disease: new insights in pathogenesis lead to new treatments. J. Hepatol. 2000 32, 113-128 (2000). (Pubitemid 30123629)
50. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 16, 1221-1231 (2002).
51. Stumptner C, Fuchsbichler A, Heid H et al. Mallory body-a disease associated type of sequestosome. Hepatology 35, 1053-1062 (2002) (Pubitemid 34454002)
52. Fickert P, Trauner M, Fuchsbichler A. Mallory body formation in primary biliary cirrhosis is associated with increased amounts and hyperphosphorylation and ubiquitination of cytokeratins. J. Hepatol. 38, 383-394 (2003).
53. Lewis DF, Ioannides C, Parke DV. Molecular orbital studies of oxygen activation and mechanisms of cytochromes P-450-mediated oxidative metabolism of xenobiotics. Chem. Biol. Interact. 70, 263-280 (1989). (Pubitemid 19164262)
54. Villeneuve JP, Pichette V. Cytochrome P450 and liver diseases. Curr. Drug Metab. 5, 273-282 (2004). (Pubitemid 38735781)
55. Strnad P, Stumptner C, Zatloukal K et al. Intermediate flament cytoskeleton of the liver in health and disease. Histochem. Cell Biol. 129, 735-749 (2008).
56. Zatloukal K, Stumptner C, Lehner M et al. Cytokeratin 8 protects from hepatotoxicity and its ratio to cytokeratin 18 determines the ability of hepatocytes to form Mallory bodies. Am. J. Pathol. 156, 1263-1274 (2000). (Pubitemid 30660005)
57. Oliva J, Bardag-Gorce F, Li J et al. Betaine prevents Mallory-Denk body formation in drug primed mice by epigenetic mechanisms. Exp. Mol. Pathol. 86, 77-86 (2009).
58. Burt AD, Mutton A, Day CP. Diagnosis and interpretation of steatosis and steatohepatitis. Semin. Diagn. Pathol. 15, 246-258 (1998). (Pubitemid 28536758)
59. Yeh M, Brunt EM. Pathology of non-alcoholic fatty liver disease. Am. J. Clin. Pathol. 128, 837-847 (2007). (Pubitemid 350133997)
60. Olofson S, Boström P, Andersson L et al. Lipid droplets as dynamic organelles connecting storage and effux of lipids. Biochim. Biophys. Acta 1791, 448-458 (2009).
61. Denk H, Stumptner C, Fuchsbichler A et al. [Alcoholic and nonalcoholic steatohepatitis. Histopathologic and pathogenetic considerations]. Pathologe 22, 388-398 (2001). (Pubitemid 33078685)
62. Ikura Y, Ohsawa M, Suekane T et al. Localization of oxidised phosphatidylcholine in nonalcoholic fatty liver disease: impact on disease progression. Hepatology 43, 506-514 (2006).
63. Fujii H, Ikura Y, Arimoto J et al. Expression of perilipin and adipophyllin in non-alcoholic fatty liver disease: relevance to oxidative injury and hepatocyte ballooning. J. Atheroscler. Thromb. 16, 893-901 (2009).
64. Caldwell SH, Chang CY, Nakamoto RK Mitochondria in non-alcoholic fatty liver disease. Clin. Liver Dis. 8, 595-617 (2004). (Pubitemid 39141145)
65. Fromentey B, Robin MA, Igoudjil A et al. The ins and outs of mitochondrial dysfunction in NASH. Diabetes Metab. 30, 121-138 (2004). (Pubitemid 38715168)
66. Alkhouri N, Dixon LJ, Feldstein AE. Lipotoxicity in non-alcoholic fatty liver disease: not all lipids are created equal. Expert Rev. Gastroenterol. Hepatol. 3, 445-451 (2009).
67. Matteoni CA, Younossi ZM, Gramlich T et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116, 1413-1419 (1999). (Pubitemid 29258890)
68. Ekstedt M, Franzen LE, Mathiesen UL et al. Long term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44, 865-873 (2006). (Pubitemid 46489550)
69. Ratziu V, Giral P, Charlotte F et al. Liver fbrosis in overweight patients. Gastroenterology 94, 2467-2474 (1999).
70. Dam-Larsen S, Franzmann M, Andersen IB et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 53, 750-755 (2003).
71. Adams LA, Lymp IF, St Sauver J et al. The natural history of non-alcoholic liver disease: a population-based cohort study Gastroenterology 129, 113-121 (2005). (Pubitemid 41002048)
72. Ong J, Pitts A, Younossi Z et al. Increased overall mortality and liver related mortality in non-alcoholic fatty liver disease. J. Hepatol. 49, 608-612 (2008).
73. Ledinghen V, Ratziu V, Causse X et al. Diagnostic and predictive factors of signifcant liver fbrosis and minimal lesions in patients with persistent unexplained elevated transaminases. A prospective multicenter study. J. Hepatol. 45, 592-599 (2006). (Pubitemid 44316865)
74. Caldwell SH, Oelsner Dh, Jezzoni JC et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 29, 664-669 (1999). (Pubitemid 29109578)
75. Poonawala A, Nair SP, Thuluvath PJ et al. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study Hepatology 32, 689-692 (2000).
76. Starley BQ, Calcagno CJ, Harrison S. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51, 1820-1832 (2010).
77. Buganiesi E, Leone N, Vanni E et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123, 134-140 (2002). (Pubitemid 34747534)
78. Hui JM, Kench JG, Chitturi S et al. Long-term outcomes of cirrhosis in non-alcoholic steatohepatitis compared with hepatitis C Hepatology 38, 420-427 (2003). (Pubitemid 36919863)
79. Ascha M, Hanouneh IA, Lopez R et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholc steatohepatitis. Hepatology 51, 1972-1978 (2010).
80. Younossi ZM, Gramlich T, Liu YC et al. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod. Pathol. 11, 560-565 (1998). (Pubitemid 28280720)